state legislation

State Laws Could Hamper Savings from Biosimilar Drugs

Posted on 05/30/2013 by |AARP Blog Author | Comments

Public Policy Institute  Many consumers have benefited from the recent increase in brand-name drugs that are going off patent, allowing less expensive generic drugs to enter the market.  The same may happen with a new type of drugs known as biologics — but only if the generic versions of these drugs are allowed to reach consumers. Biologic drugs are medicines derived from living organisms that are often used to treat health conditions that commonly affect older populations, such as cancer, multiple sclerosis …